HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Risk factors for recurrence and severity of an ulcerative colitis attack

DOI: https://doi.org/10.29296/25877305-2022-05-08
Issue: 
5
Year: 
2022

Professor E. Bolotova(1), MD; K. Yumukyan(1, 2); A. Dudnikova(1), Candidate of Medical Sciences; M. Yakovenko(2), Candidate of Medical Sciences
1-Kuban State Medical University, Ministry of Health of Russia, Krasnodar
2-Research Institute – S.V. Ochapovsky Territorial Clinical Hospital One, Krasnodar

Objective. To analyze risk factors for recurrence and severity of an ulcerative colitis (UC) attack. Material and methods. A retrospective study that included 315 medical records of UC patients (167 and 148 inpatient and outpatient records, respectively) was conducted. Results. Patients with recurrent UC requiring hospitalization were observe to have statistically significantly increases in the duration of the disease, in the frequency of exacerbations/exacerbations in their history and the frequency of using biological agents, a younger age at the onset of UC, a low status of current smoking and ex-smoking as compared with those in patients in remission. Severe UC was associated with the following factors: a young age at the onset of UC; a lower body mass index, a history of biological therapy; a positive fecal occult blood test at the time of hospitalization; lower hemoglobin and albumin levels; higher erythrocyte sedimentation rate and C-reactive protein; a large extent of intestinal damage; and deep ulcerative defects in the colon mucosa. Conclusion. Analysis of risk factors for recurrence and severity of an UC attack aids in the personalization of treatment, in the prediction of therapeutic response, in the evaluation of the likelihood of adverse effects, and in the optimization of the early diagnosis of the risk of relapse in UC and its severe attack.
Keywords: 
gastroenterology; risk of recurrence in ulcerative colitis; severity of ulcerative colitis attack; risk factors

References: 
  1. Holvoet T., Lobaton T., Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol. 2021; 14: 71–81. DOI: 10.2147/CEG.S197719
  2. Gallo G., Kotze P.G., Spinelli A. Surgery in ulcerative colitis: When? How? Best Pract Res Clin Gastroenterol. 2018; 32–33: 71–8. DOI: 10.1016/j.bpg.2018.05.017
  3. Tertychny A.S., Akhrieva Kh.M., Maev I.V. et al. Diagnostic problems of histological remission in patients with inflammatory bowel disease. Arkhiv Patologii. 2017; 79 (3): 3–9 (in Russ.). DOI: 10.17116/patol20177933-9
  4. Ivashkin V.T., Shelygin Yu.A., Abdulganiyeva D.I. et al. Guidelines of the Russian gastroenterological association and Russian Association of Coloproctology on diagnostics and treatment of ulcerative colitis in adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015; 25 (1): 48–65 (in Russ.).
  5. Frolkis A.D., Dykeman J., Negrón M.E. et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013; 145 (5): 996–1006. DOI: 10.1053/j.gastro.2013.07.041
  6. Lamb C.A., Kennedy N.A., Raine T. et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults [published correction appears in Gut. 2021; 70 (4): 1]. Gut. 2019; 68 (3): s1-s106. DOI: 10.1136/gutjnl-2019-318484
  7. Mathurin F. et al. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018; 16 (3): 343-356.e3. DOI: 10.1016/j.cgh.2017.06.016
  8. Bopanna S., Ananthakrishnan A.N., Kedia S. et al. Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017; 2 (4): 269–76. DOI: 10.1016/S2468-1253(17)30004-3
  9. Kotze P.G., Steinwurz F., Francisconi C. et al. Review of the epidemiology and burden of ulcerative colitis in Latin America. Ther Adv Gastroenterol. 2020; 13: 1756284820931739. DOI: 10.1177/1756284820931739
  10. Bikbavova G.R., Livzan M.A., Novikov D.G. et al. Precision medicine and inflammatory bowel diseases: concept, strategies, future. Experimental and Clinical Gastroenterology. 2021; 1 (6): 121–9 (in Rus.). DOI: 10.31146/1682-8658-ecg-190-6-121-129
  11. Kucharzik T., Koletzko S., Kannengiesser K. et al. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms. Dtsch Arztebl Int. 2020; 117 (33–34): 564–74. DOI: 10.3238/arztebl.2020.0564
  12. Oh S.J., Shin G.Y., Soh H. et al. Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis. Intest Res. 2021; 19 (3): 323–31. DOI: 10.5217/ir.2020.00039
  13. Lau A., Chande N., Ponich T. et al. Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2008; 28 (5): 606–13. DOI: 10.1111/j.1365-2036.2008.03772.x
  14. Tanaka M., Takagi T., Naito Y. et al. Low serum albumin at admission is a predictor of early colectomy in patients with moderate to severe ulcerative colitis. JGH Open. 2021; 5 (3): 377–81. DOI: 10.1002/jgh3.12506
  15. Wagatsuma K., Yokoyama Y., Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel). 2021; 11 (12): 1375. DOI: 10.3390/life11121375
  16. Kato J., Yoshida T., Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol. 2019; 15 (6): 667–77. DOI: 10.1080/1744666X.2019.1593140
  17. Burisch J., Ungaro R., Vind I. et al. Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort. J Crohns Colitis. 2017; 11 (10): 1200–4. DOI: 10.1093/ecco-jcc/jjx066